TSX Penny Stocks With Market Caps Under CA$200M
As we head into the second half of 2025, the Canadian market is navigating a landscape shaped by ongoing tariff and trade negotiations, which could influence economic growth and inflation. Despite these uncertainties, the potential for positive economic growth remains, especially as both Canada and the U.S. are largely service-driven economies. In this context, penny stocks—often representing smaller or newer companies—continue to be an intriguing investment area due to their potential for significant returns when backed by strong financial health.
Name
Share Price
Market Cap
Financial Health Rating
PetroTal (TSX:TAL)
CA$0.69
CA$640.24M
★★★★★☆
Orezone Gold (TSX:ORE)
CA$1.24
CA$665.6M
★★★★★☆
Dynacor Group (TSX:DNG)
CA$4.40
CA$189.71M
★★★★★★
Findev (TSXV:FDI)
CA$0.445
CA$12.6M
★★★★★★
Thor Explorations (TSXV:THX)
CA$0.77
CA$518.93M
★★★★★★
Automotive Finco (TSXV:AFCC.H)
CA$0.89
CA$17.44M
★★★★★★
NTG Clarity Networks (TSXV:NCI)
CA$2.26
CA$98.22M
★★★★★★
Intermap Technologies (TSX:IMP)
CA$2.19
CA$125.23M
★★★★★☆
Hemisphere Energy (TSXV:HME)
CA$1.95
CA$185.99M
★★★★★★
McChip Resources (TSXV:MCS)
CA$1.00
CA$5.65M
★★★★★★
Click here to see the full list of 890 stocks from our TSX Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Psyched Wellness Ltd. is a health supplements company that produces and distributes mushroom-derived products and related consumer packaged goods in the United States, with a market cap of CA$8.66 million.
Operations: The company generates revenue from its Vitamins & Nutrition Products segment, amounting to CA$0.64 million.
Market Cap: CA$8.66M
Psyched Wellness Ltd. is a pre-revenue company with CA$0.64 million in sales, facing auditor concerns about its ability to continue as a going concern. Despite having no debt and sufficient short-term assets (CA$6.7M) to cover liabilities (CA$234.9K), it remains unprofitable with increasing losses over the past five years at 14.7% annually. The stock's volatility is high, yet stable compared to previous periods, and shareholders have not faced significant dilution recently. A recent pilot for a new dietary supplement may offer future revenue potential if successful in consumer testing and market launch preparations are completed effectively.
Unlock comprehensive insights into our analysis of Psyched Wellness stock in this financial health report.
Review our historical performance report to gain insights into Psyched Wellness' track record.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Sailfish Royalty Corp. focuses on acquiring precious metals royalty and streaming agreements, with a market cap of CA$185.49 million.
Operations: The company generates revenue of $3.07 million from its royalties and stream interests.
Market Cap: CA$185.49M
Sailfish Royalty Corp. has a market cap of CA$185.49 million and is not pre-revenue, with US$0.59 million in revenue for Q1 2025 despite a net loss of US$0.075 million compared to the previous year's profit. The company benefits from its 2% net smelter return royalty on Mako Mining's El Golfo area, where promising drill results have been reported, potentially enhancing future cash flows and resource expansion opportunities. While Sailfish's earnings grew significantly last year, its forecasted decline in earnings presents a challenge alongside limited interest coverage by EBIT and dividends not well covered by earnings or free cash flow.
Click here to discover the nuances of Sailfish Royalty with our detailed analytical financial health report.
Understand Sailfish Royalty's earnings outlook by examining our growth report.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: NeoTerrex Minerals Inc. is involved in the evaluation, acquisition, and exploration of mineral properties in Canada with a market cap of CA$14.96 million.
Operations: NeoTerrex Minerals Inc. does not currently report any revenue segments.
Market Cap: CA$14.96M
NeoTerrex Minerals Inc., with a market cap of CA$14.96 million, is pre-revenue and focuses on mineral exploration in Canada. The company has no debt and maintains a cash runway exceeding one year under stable conditions. Recent announcements highlight fully-funded exploration plans targeting rare earth elements across several projects, including Mount Discovery and Galactic REE projects, leveraging favorable tax incentives. Despite its unprofitability, NeoTerrex's strategic focus on critical minerals positions it for potential future value creation pending successful exploration outcomes. However, the stock remains highly volatile with significant price fluctuations observed recently.
Navigate through the intricacies of NeoTerrex Minerals with our comprehensive balance sheet health report here.
Explore historical data to track NeoTerrex Minerals' performance over time in our past results report.
Click through to start exploring the rest of the 887 TSX Penny Stocks now.
Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CNSX:PSYC TSXV:FISH and TSXV:NTX.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
12 minutes ago
- Hamilton Spectator
High Arctic Announces Annual General and Special Meeting Results
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, June 20, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the 'Corporation' or 'High Arctic') is pleased to announce the results of the annual general and special meeting of the shareholders of High Arctic held on June 19, 2025 (the 'Meeting'). 32 shareholders holding a total of 8,570,252 common shares of the Corporation were represented at the Meeting in person or proxy, representing approximately 67.50% of the total votes attached to all issued and outstanding common shares of the Corporation as of the record date on May 12, 2025. All matters put forth at the Meeting were approved. In respect of the election of directors, the shareholders approved fixing the number of directors at four with each nominee named in the Corporation's management information circular dated May 26, 2025 being considered for election as directors. The detailed results of the vote for the election of directors, which was conducted by ballot, are set out below: At the Meeting, the shareholders also approved a resolution appointing MNP LLP, Chartered Professional Accountants, as auditors of the Corporation and a resolution approving a new omnibus equity incentive plan of the Corporation, to replace the existing stock option plan, performance share unit plan, and deferred share unit plan. About High Arctic Energy Services High Arctic is an energy services provider. High Arctic provides pressure control equipment and equipment supporting the high-pressure stimulation of oil and gas wells and other oilfield equipment on a rental basis to exploration and production companies, from its bases in Whitecourt and Red Deer, Alberta. For further information contact: Lonn Bate Chief Financial Officer P: 587-318-2218 P: +1 (800) 688 7143 High Arctic Energy Services Inc. Suite 2350, 330 – 5th Ave SW Calgary, Alberta, Canada T2P 0L4 website: Email: info@
Business Wire
34 minutes ago
- Business Wire
SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ('Advantech/Prime') Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the 'Dissenting Investor Group') to wrest control of SINOVAC from its recently installed, lawfully-elected Board of Directors (the 'current SINOVAC Board') in accordance with the Privy Council order and Antiguan Law, and to interfere with the payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. Following the New York court's ruling, the current SINOVAC Board is free to pursue its legal action in Antigua seeking to cancel the PIPE shares invalidly issued to the Dissenting Investor Group by the former illegitimate board (the 'Imposter Former Board'). If the current SINOVAC Board succeeds in legal proceedings on the PIPE shares, it has announced its intention to redistribute an additional US$11.00 per common share to SINOVAC's valid shareholders. Dr. Chiang Li, Chairman of the SINOVAC Board, commented, 'We will continue our mission to restore fairness and deliver value to all valid SINOVAC shareholders, starting with paying the $55.00 per share special cash dividend as soon as July 7, 2025.' The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy against SINOVAC has one goal: to prevent all valid SINOVAC common shareholders from receiving any dividend payments unless the Dissenting Investor Group receives an allocation for their invalid PIPE shares, despite the fact that they have already received over US$1 billion in dividends from a SINOVAC operating subsidiary. The current SINOVAC Board has set aside in escrow the pro rata portion of dividends for the PIPE shares — funds the Dissenting Investor Group could receive if the legal proceedings they initiated rule in their favor. The current SINOVAC Board is fighting back – and winning. We feel certain that we will prevail against any further legal action by the Dissenting Investor Group and look forward to ensuring all valid shareholders receive their fair share. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Insider
an hour ago
- Business Insider
'Roadblock': Paramount Stock (NASDAQ:PARA) Surges as the Trump Settlement Sputters
As it turns out, entertainment giant Paramount (PARA) was actually fairly close to a deal with President Trump over the 60 Minutes lawsuit. But, when the deal was fairly close, a 'roadblock' emerged and put a halt to the whole matter, at least for now. Investors reacted with surprising strength, and perhaps even more surprising positivity. Paramount shares gained nearly 2.5% in the closing minutes of Friday's trading. Confident Investing Starts Here: The settlement had reached $35 million, reports noted, when Paramount suddenly found itself paralyzed by indecision. That delay caused Trump lawyers to pivot and pull back to their original demand, calling for a $50 million settlement. The biggest problem seems to be that the Federal Communications Commission (FCC) is also involved in this, and needs to sign off on the merger with Skydance as well. Reports suggested that Paramount brass believes that the FCC's sign-off on the deal needs to be contingent on settling the case, but by like token, the idea that requiring FCC approval as part of the settlement looks a lot like a bribe. Trump's legal team, reports note, has already been clear that the Trump suit and the FCC case are two separate matters. But with outside organizations looking to launch their own lawsuits should the settlement go through, looks may count for more here than anyone expected. South Park Losses Mount Meanwhile, as Paramount faces the prospect of losing South Park exclusivity, it quietly pulled another old episode from the field. The pull this time showed up in the Canadian and Australian markets, reports noted, and this time, featured Butters' Very Own Episode pulled from Paramount+. Why, however, is a bit of a mystery. Several South Park episodes are apparently a bit too spicy for streaming, in retrospect, with around a dozen classic episodes set to be pulled from the catalog and relegated to a 'ban list', reports noted. The reports got stranger as an Australian viewer noted that the Paramount+ listing had been pulled, but the episode could still be watched by watching through Paramount+ on Amazon (AMZN) Prime Video. Is Paramount Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Hold consensus rating on PARA stock based on two Buys, eight Holds and five Sells assigned in the past three months, as indicated by the graphic below. After a 18.62% rally in its share price over the past year, the average PARA price target of $12.08 per share implies 2.23% downside risk.
